<DOC>
	<DOCNO>NCT01784302</DOCNO>
	<brief_summary>This study seek address question whether antacid multivitamin influence pharmacokinetics raltegravir co-administered . The aim study optimise dose raltegravir co-administered antacid multivitamin .</brief_summary>
	<brief_title>The Effect Antacids Multivitamins Raltegravir</brief_title>
	<detailed_description />
	<mesh_term>Aluminum hydroxide , magnesium hydroxide , drug combination</mesh_term>
	<mesh_term>Antacids</mesh_term>
	<mesh_term>Aluminum hydroxide , magnesium hydroxide , simethicone drug combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>TEMPO</mesh_term>
	<criteria>The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement . ≥ 18 year Male female subject A female may eligible enter participate study : Is nonchildbearing potential define ether postmenopausal ( 12 month spontaneous amenorrhea ≥ 45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy Is childbearing potential negative pregnancy test screening agree use one follow method contraception avoid pregnancy Complete abstinence intercourse 2 week prior administration IP , throughout study least 4 week discontinuation study medication Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year Any method publish data show expected failure rate &lt; 1 % per year Hormonal contraception plus barrier method . Hormonal contraception alone consider adequate inclusion participation study Male subject female partner childbearing potential must agree use effective contraception unless vasectomize All subject participate study counsel safe sexual practice include use effective barrier method ( e.g . male condom ) Any significant acute chronic medical condition Pregnant lactate woman Women childbearing age unless use non hormonal contraception Evidence organ dysfunction clinically significant deviation normal screen include laboratory determination Abnormal LFTs ( ALT &gt; 2.5 x ULN , bilirubin &gt; 1.5 x ULN ) Positive blood screen HIV1 2 antibody Positive blood screen hepatitis B C antibody Current recent ( within 3 month ) gastrointestinal disease Clinically relevant alcohol drug use history alcohol drug use hinder compliance treatment , follow procedure evaluation adverse effect Use proton pump inhibitor Exposure investigational drug placebo within 4 week first dose study drug Consumption grapefruit oranges product contain grapefruit orange within 1 week first study drug duration study Use drug include overthecounter medication herbal preparation , within 2 week prior first dose study drug Previous allergy constituent pharmaceutical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>